主辦 / 主持人
台灣百靈佳殷格翰(股)公司
積分
B類 4 分
分類
未分類
聯絡人
Joe 0905889135
活動日期
2021-01-23 (六) 15:00 ~ 18:30
2021-01-24 (日) 09:00 ~ 12:30
地點
W hotel Taipei 8 樓 Great room (台北市信義區忠孝東路5段10號 8 樓)
說明

IPF is characterized as a progressive, highly life-threatening interstitial lung disease with unknown etiology. The median survival of patients with IPF is only 2 to 3 years. It occurs primarily in elders, is limited to the lungs, and is defined by the histopathologic and/or radiologic pattern of UIP. It should be considered in all adult patients with unexplained chronic exertional dyspnea, cough, bibasilar inspiratory crackles, and/or digital clubbing that occur without constitutional or other symptoms that suggest a multisystem disease. Patients with IPF may present with an acute exacerbation as an initial manifestation. The disease course is unpredictable and various, so early IPF detection and immediate treatment are crucial to the preservation of patients’ lung function. Beyond IPF, the presentation, diagnosis, and clinical course of Progressive-fibrosing ILD (PF-ILD) have shown similarity with IPF. PF-ILD usually is associated with autoimmune disease (e.g., SSc-ILD, RA-ILD, DM-ILD, Sjogren syndrome associated ILD), fibrotic chronic hypersensitivity pneumonitis, sarcoidosis, or related to occupational environment exposure. In this meeting, we will deep dive into the terminology and clinical courses of PF-ILD, current experts’ consensus of PF-ILD disease definition, optimal timing of the antifibrotics initiation, the rationale & key results of INBUILD study and case mimics with hands-on visualized analysis on HRCT (semi-quantification). Hopefully, this meeting could provide physicians useful guidance on the diagnosis and treatment in PF-ILD, and take it into their daily practices.

2021-01-23 W hotel Taipei 8 樓 Great room (台北市信義區忠孝東路5段10號 8 樓)
時間主題
沒有資料